Cancer Cell Cytotoxicity of Marinopyrroles, Pyrrolomycins, and Their Derivatives

Marine-derived secondary metabolites have emerged as a rich potential source of anticancer agents, with marinopyrroles and pyrrolomycins representing structurally distinct halogenated pyrroles of interest. Initially characterized for their potent antibacterial properties, these compounds were later shown to exert cytotoxic activity across diverse hematologic and solid malignancies, frequently correlating with Mcl-1 dependence. Marinopyrrole A, a marine-derived natural product, exemplified this potential by inducing proteasomal degradation of Mcl-1, thereby sensitizing resistant cancer cells to Bcl-2 inhibitors and TRAIL-based therapies. In parallel, pyrrolomycins, particularly pyrrolomycin C and members of the F-series, demonstrated potent activity with submicromolar IC₅₀ concentrations across multiple cancer cell lines, and also perturbed cytoskeletal and membrane integrity. Together, these halogenated pyrroles illustrate multifaceted cancer cell cytotoxicity profiles but face translational barriers, including mechanistic ambiguity, poor solubility, and off-target toxicities. To address these limitations, extensive medicinal chemistry efforts have yielded synthetic derivatives with improved potency, selectivity, and drug-like properties, with notable examples such as MP1 and KS18 showing enhanced efficacy in MYC-driven neuroblastoma, medulloblastoma, and drug-resistant multiple myeloma.